Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
ObjectiveThe aim of this study is to compare gemcitabine (G) plus docetaxel (D) versus G plus anlotinib (A) for advanced soft tissue sarcoma (STS).MethodsWe retrospectively investigated 122 patients with locally advanced or metastatic STS who were treated with either G+D or G+A between July 2016 and...
Main Authors: | Zhiyong Liu, Xin Wang, Jiaqiang Wang, Peng Zhang, Chao Li, Bangmin Wang, Guancong Liu, Weitao Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.922127/full |
Similar Items
-
Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
by: María López-Álvarez, et al.
Published: (2022-12-01) -
Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
by: Sun X, et al.
Published: (2022-09-01) -
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
by: Steven Attia, et al.
Published: (2023-10-01) -
The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
by: Wang T, et al.
Published: (2022-10-01) -
Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
by: Minggui Pan, et al.
Published: (2021-04-01)